{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196465","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.228476+00:00","generated_at":"2026-05-31T10:49:43.492690+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN","bullets":["Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.","Key secondary endpoints met: composite renal endpoint and ≥50% proteinuria reduction.","Favorable safety profile; no meningitis or serious infections from encapsulated bacteria.","All VALIANT completers enrolled in long-term extension study VALE.","Apellis to file sNDA with FDA in early 2025; Sobi to submit EMA application in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196465","json":"https://secwatch.observer/filing/0001193125-24-196465.json","markdown":"https://secwatch.observer/filing/0001193125-24-196465.md","text":"https://secwatch.observer/filing/0001193125-24-196465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524196465/0001193125-24-196465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524196465/d848612d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:49:43.492690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}